Related Experiment Video
Updated: Jun 20, 2026
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Design and development of polymer conjugates as anti-angiogenic agents
Ehud Segal1, Ronit Satchi-Fainaro
1Department of Physiology and Pharmacology, Sackler School of Medicine, Room 607, Tel Aviv University, Tel Aviv 69978, Israel.
Abstract:
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is one of the central key steps in tumor progression and metastasis. Consequently, it became an important target in cancer therapy, making novel angiogenesis inhibitors a new modality of anticancer agents. Although relative to conventional chemotherapy, anti-angiogenic agents display a safer toxicity profile, the vast majority of these agents are low-molecular-weight compounds exhibiting poor pharmacokinetic profile with short half-life in the bloodstream and high overall clearance rate. The "Polymer Therapeutics" field has significantly improved the therapeutic potential of low-molecular-weight drugs and proteins for cancer treatment. Drugs can be conjugated to polymeric carriers that can be either directly conjugated to targeting proteins or peptides or derivatized with adapters conjugated to a targeting moiety. This approach holds a significant promise for the development of new targeted anti-angiogenic therapies as well as for the optimization of existing anti-angiogenic drugs or polypeptides. Here we overview the innovative approach of targeting tumor angiogenesis using polymer therapeutics.
Insights
Polymer therapeutics offer a promising strategy to enhance anti-angiogenic cancer treatments. This approach improves drug delivery and targeting for novel anticancer agents, optimizing tumor blood vessel inhibition.
Area of Science:
- Oncology
- Biomaterials Science
- Pharmacology
Background:
- Tumor angiogenesis, the formation of new blood vessels, is crucial for cancer growth and metastasis.
- While anti-angiogenic agents offer a safer alternative to chemotherapy, many suffer from poor pharmacokinetics.
- Polymer therapeutics present an innovative solution to overcome these limitations.
Purpose of the Study:
- To review the application of polymer therapeutics in targeting tumor angiogenesis.
- To highlight the potential of polymer-drug conjugates for enhanced anti-cancer therapy.
Main Methods:
- Overview of polymer conjugation strategies for drug delivery.
- Discussion of targeting moieties and adapter systems in polymer therapeutics.
- Review of existing and novel anti-angiogenic drugs and polypeptides.
Main Results:
- Polymer conjugation can significantly improve the pharmacokinetic profiles of anti-angiogenic agents.
- Targeted delivery systems enhance the efficacy of anti-angiogenic therapies.
- Polymer therapeutics offer a versatile platform for developing next-generation cancer treatments.
Conclusions:
- Polymer therapeutics represent a significant advancement in targeting tumor angiogenesis.
- This approach holds promise for optimizing existing anti-angiogenic drugs and developing novel targeted therapies.
- The field of polymer therapeutics offers innovative strategies for improving cancer treatment outcomes.
